{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:52Z","timestamp":1792191952674,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,10,12]],"date-time":"2014-10-12T00:00:00Z","timestamp":1413072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00277-014-2231-9","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T05:19:12Z","timestamp":1413177552000},"page":"393-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment"],"prefix":"10.1007","volume":"94","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zacheo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Serrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,12]]},"reference":[{"key":"2231_CR1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203","journal-title":"Leukemia"},{"key":"2231_CR2","first-page":"632","volume":"114","author":"G Saglio","year":"2013","unstructured":"Saglio G, Hochhaus A, Hughes TP, Clark RE, Nakamae H, Kim DW et al (2013) ENESTnd update: nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase and the impact of early molecular response and Sokal risk at diagnosis on long-term outcomes. Blood 114:632","journal-title":"Blood"},{"key":"2231_CR3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533\u2013539","journal-title":"Am J Hematol"},{"key":"2231_CR4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Coutre le","year":"2011","unstructured":"le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndhofer S et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347\u20131348","journal-title":"J Natl Cancer Inst"},{"key":"2231_CR5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"F Giles","year":"2013","unstructured":"Giles F, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al (2013) Rate of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27:1310\u20131315","journal-title":"Leukemia"},{"key":"2231_CR6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316\u20131321","journal-title":"Leukemia"},{"key":"2231_CR7","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood.V122.21.1489.1489","volume":"122","author":"P Coutre le","year":"2013","unstructured":"le Coutre P, Hughes T, Mahon FX, Kim DW, Steegmann JL, Shah NP et al (2013) Peripheral arterial occlusive disease (PAOD) in patients (pts) receiving dasatinib: experience across multiple clinical trials. Blood 122:1489","journal-title":"Blood"},{"key":"2231_CR8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12529-012-9242-5","volume":"19","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 19:403\u2013488","journal-title":"Int J Behav Med"},{"key":"2231_CR9","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Larson RA, Hughes TP, Issaragrisil S, Turkina AG, Marin D et al (2010) Efficacy and safety of nilotinib in chronic phase chronic myeloid leukemia patients with type 2 diabetes in the ENESTnd trial. Blood 116:3430","journal-title":"Blood"},{"key":"2231_CR10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood.V120.21.1686.1686","volume":"120","author":"D Rea","year":"2012","unstructured":"Rea D, Gautier JF, Breccia M, Saglio G, Hughes TP, Kantarjian H et al (2012) Incidence of hyperglycemia by 3\u00a0years in patients with newly diagnosed of chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib in ENESTnd. Blood 120:1686","journal-title":"Blood"},{"key":"2231_CR11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V122.21.1503.1503","volume":"122","author":"DK Hiwase","year":"2013","unstructured":"Hiwase DK, Carne L, Ross D, Grigg A, Hughes TP (2013) Hypercholesterolemia in imatinib intolerant\/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood 122:1503","journal-title":"Blood"},{"key":"2231_CR12","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood.V122.21.4042.4042","volume":"122","author":"D Rea","year":"2013","unstructured":"Rea D, Mirault T, Gaultier JF, Guilhot F, Messas E, Dombret H (2013) Prospective analysis of plasma cholesterol and triglycerides in patients with chronic phase-chronic myeloid leukemia during treatment with the 2nd generation tyrosine kinase inhibitor nilotinib. Blood 122:4042","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2231-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2231-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T18:53:32Z","timestamp":1598381612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2231-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,12]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2231-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,12]]}}}